The Korean Society of Hypertension published new guidelines for the management of hypertension in 2013 which fully revised the first Korean hypertension treatment guideline published in 2004.Due to shortage of Korean data, the Committee decided to establish the guideline in the form of an adaptation of the recently released guidelines.The prevalence of hypertension was 28.5% in the recent Korean National Health and Nutrition Examination Survey in 2011, and the awareness, treatment, and control rates are generally improving.However, the risks for cerebrovascular disease and coronary artery disease which are attributable to hypertension were the highest in Korea.The classification of hypertension is the same as in other guidelines.The remarkable difference is that prehypertension is further classified as stage 1 and 2 prehypertension because the cardiovascular risk is significantly different within the prehypertensive range.Although the decision-making was based on office blood pressure (BP) measured by the auscultation method using a stethoscope, the importance of home BP measurement and ambulatory BP monitoring is also stressed.The Korean guideline does not recommend a drug therapy in patients within the prehypertensive range, even in patients with prediabetes, diabetes mellitus, stroke, or coronary artery disease.In an elderly population over 65 years old, drug therapy can be initiated when the systolic BP (SBP) is ≥160 mm Hg.The target BP is generally an SBP of <140 mm Hg and a diastolic BP (DBP) of <90 mm Hg regardless of previous cardiovascular events.However, in patients with hypertension and diabetes, the lower DBP control <85 mm Hg is recommended.Also, in patients with hypertension with prominent albuminuria, a more strict SBP control <130 mm Hg can be recommended.In lifestyle modification, sodium reduction is the most important factor in Korea.Five classes of antihypertensive drugs, including angiotensin-converting enzyme inhibitors, β-blockers, calcium antagonists, and diuretics, are equally recommended as a first-line treatment, whereas a combination therapy chosen from renin-angiotensin system inhibitors, calcium antagonists,and diuretics is preferentially recommended.